Tirzepatide vs Semaglutide vs Retatrutide: The Complete GLP-1 Comparison 2026

Key Takeaways

• The three drugs differ by how many incretin receptors they activate: semaglutide hits GLP-1 only, tirzepatide adds GIP (dual agonist), and retatrutide adds glucagon on top (triple agonist). More targets has so far meant more weight loss.
• Peak trial weight loss: semaglutide ~15% (STEP-1), tirzepatide ~22.5% (SURMOUNT-1), retatrutide ~24% at 48 weeks in a Phase 2 trial — though retatrutide is not yet approved.
• Semaglutide has the deepest outcomes data, including a 20% reduction in cardiovascular events (SELECT). Tirzepatide is the most potent approved option. Retatrutide is the most powerful in trials but still investigational.
• All three drive significant lean-mass loss — typically 25-40% of total weight lost is fat-free mass. Protein intake and resistance training are non-negotiable.
• These are prescription drugs with real contraindications. Source only FDA-approved products or verified 503B pharmacies.

The Whole Story Is in the Receptor Count

If you only remember one thing from this comparison, make it this: these three drugs are best understood as a progression, defined by how many incretin receptors each one activates.

• Semaglutide activates one: GLP-1.
• Tirzepatide activates two: GLP-1 and GIP.
• Retatrutide activates three: GLP-1, GIP, and glucagon.

Each added receptor brings a new metabolic lever, and so far, each step up the ladder has delivered more weight loss in trials. That's the headline. The rest of this article is the detail that actually matters when you — or your physician — are choosing between them: how big the differences really are, what you trade for that extra potency, and why none of it works without the muscle-preservation piece.

Tirzepatide (Mounjaro / Zepbound)

Semaglutide: The Validated Standard

Semaglutide (Ozempic for diabetes, Wegovy for obesity) is the drug that started the cultural moment. It's a GLP-1 receptor agonist with 94% structural homology to human GLP-1, modified for a once-weekly half-life.

Mechanism: It activates GLP-1 receptors across four tissues — the pancreas (more insulin, less glucagon), the hypothalamus (appetite suppression), the stomach (slowed gastric emptying), and the cardiovascular system (direct vascular benefits).

Weight loss: In the STEP-1 trial, participants on 2.4mg/week lost an average of ~15% of body weight over 68 weeks. That was unprecedented for a non-surgical intervention when it published.

The trump card — outcomes data: Semaglutide's real differentiator isn't weight loss; it's the SELECT trial, which showed a 20% reduction in major cardiovascular events in people with obesity and existing heart disease, independent of how much weight they lost. No other drug in this class has matched that depth of hard-outcome evidence. If cardiovascular protection is the goal, semaglutide currently has the strongest case.

Tirzepatide: The Potent Approved Option

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) added a second receptor — GIP — to the GLP-1 backbone. It's a dual agonist, and the addition turned out to matter a great deal.

Mechanism: Alongside the full GLP-1 effect, tirzepatide activates GIP receptors. GIP agonism improves insulin sensitivity, appears to enhance the appetite and weight effects, and — counterintuitively — may improve gastrointestinal tolerability relative to the degree of weight loss achieved.

Weight loss: In SURMOUNT-1, the 15mg dose produced ~22.5% average body-weight loss over 72 weeks. That's roughly a third more than semaglutide.

The head-to-head: This isn't just cross-trial comparison. In SURPASS-2, tirzepatide was tested directly against semaglutide in people with type 2 diabetes — and tirzepatide produced significantly greater reductions in both HbA1c and body weight. When two drugs are compared in the same trial, the result carries far more weight than comparing separate studies, and tirzepatide won.

The honest gap: Tirzepatide does not yet have a published cardiovascular-outcomes trial on the scale of SELECT. Its potency is established; its hard-outcome story is still being written.

Retatrutide: The Investigational Powerhouse

Retatrutide adds the third receptor — glucagon — to make a triple agonist. It is not yet approved; everything we know comes from Phase 2 data and ongoing Phase 3 trials.

Mechanism: It does everything tirzepatide does, plus glucagon-receptor agonism. Glucagon, in this context, increases energy expenditure and hepatic fat oxidation. So where GLP-1 and GIP mostly work by reducing intake, the glucagon arm also nudges the output side of the energy equation.

Weight loss: In its Phase 2 trial, the highest dose produced ~24% average weight loss at 48 weeks — and critically, the weight-loss curve had not clearly plateaued, suggesting the ceiling may be even higher over a longer course. For a metabolic drug, that trajectory is remarkable.

The caveats that matter: Glucagon agonism can raise glucose and heart rate, so the metabolic and cardiovascular safety profile needs the scrutiny that only large Phase 3 trials provide. Retatrutide is the most powerful agent in this class on paper — and also the one with the least long-term human safety data. Promising is not the same as proven.

Head-to-Head Comparison

What They All Share: The Muscle Problem

Here's the part that the weight-loss headlines bury, and the single most important thing to internalize before starting any of these drugs.

All incretin drugs cause lean-mass loss. Across trials, roughly 25-40% of the total weight lost is fat-free mass — predominantly skeletal muscle. This isn't a flaw unique to one drug; it's a feature of rapid weight loss driven primarily by appetite suppression. When intake drops sharply and you're not actively defending muscle, the body sheds it alongside fat.

The consequences aren't cosmetic. Muscle is the primary site of glucose disposal, a major determinant of resting metabolic rate, and the single best predictor of physical function and independence as you age. Losing 10kg where 3-4kg is muscle leaves you lighter but metabolically and functionally worse off than the scale suggests — and primes you for faster weight regain once the drug stops.

The fix is not optional:

• Protein: 1.6-2.2g per kg of body weight per day, which becomes genuinely hard to hit when the drug has crushed your appetite. This usually requires deliberate planning and often protein supplementation.
• Resistance training: 2-4 sessions per week providing the mechanical signal that tells the body to keep muscle. Cardio does not substitute for this.
• Adequate dosing discipline: titrating slowly rather than racing to the top dose limits the rate of loss.

We cover the full muscle-preservation system in a dedicated protocol, linked below. Treat it as part of the prescription, not an afterthought.

How to Think About Choosing

This is a medical decision made with a prescriber, but the framework is straightforward:

• If cardiovascular protection is the priority (existing heart disease, high risk): semaglutide has the outcomes data nothing else can yet match.
• If maximum approved weight loss is the priority: tirzepatide is the most potent option you can actually get prescribed today, with head-to-head superiority over semaglutide.
• If you're watching the frontier: retatrutide is the most powerful agent in development, but "in development" is doing real work in that sentence — wait for Phase 3 safety and approval.
• Tolerability and cost often decide in practice. GI side effects, insurance coverage, and supply all vary, and the "best" drug you can't tolerate or afford loses to the good-enough drug you can.

Sourcing and Safety

These are prescription medications, and the grey market around them is genuinely dangerous. Counterfeit and mislabeled "research peptides" sold as semaglutide, tirzepatide, or retatrutide are common, with documented cases of wrong doses, wrong compounds, and contamination.

• Use only FDA-approved branded products or a verified 503B compounding pharmacy operating legally.
• Respect the contraindications: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, and pregnancy.
• Titrate slowly under medical supervision to manage nausea and limit muscle loss.

The potency that makes these drugs remarkable is the same potency that makes cutting corners on sourcing and supervision a bad idea.

Frequently Asked Questions

Which is better for weight loss, tirzepatide or semaglutide?

In the head-to-head SURPASS-2 trial, tirzepatide produced significantly greater weight loss than semaglutide in people with type 2 diabetes, and cross-trial data in obesity point the same way (~22.5% vs ~15%). Tirzepatide is the more potent of the two. Semaglutide's advantage is its deeper cardiovascular-outcomes evidence. For raw weight loss, tirzepatide; for proven heart-event reduction, semaglutide.

Is retatrutide available to buy yet?

No. Retatrutide is investigational and not approved by the FDA or EMA as of 2026 — it's in Phase 3 trials. Any product sold online as "retatrutide" is unregulated grey-market material with no quality assurance, no dosing standardization, and real safety risk. The Phase 2 results are genuinely exciting, but excitement is not approval.

Will I lose muscle on these drugs?

Yes, to some degree — roughly 25-40% of total weight lost is typically fat-free mass across trials. This is inherent to rapid, appetite-driven weight loss, not a defect of a particular drug. You can substantially blunt it with adequate protein (1.6-2.2g/kg/day) and consistent resistance training. Skipping those means losing more muscle than necessary and regaining weight faster afterward.

Can you stack these drugs together?

No. Semaglutide, tirzepatide, and retatrutide all act on overlapping incretin receptors, so combining them stacks side effects and risks without a clear added benefit — you use one, not several. The meaningful "stacking" is pairing your chosen incretin drug with muscle-preserving inputs (protein, creatine, resistance training) and, in some protocols, an off-cycle metabolic bridge like berberine.

What happens when you stop taking them?

Appetite returns and, without lifestyle changes locked in, weight regain is common — trials show substantial regain after discontinuation. These drugs manage a chronic condition; they don't cure it. The people who keep weight off treat the drug as a tool that buys them the appetite control to build durable habits — protein, training, sleep — that hold after tapering.

Related Research

• Why GLP-1 Agonists Cause Muscle Loss (And How to Prevent It)
• The Lean GLP-1 Protocol: Preserving Muscle on Tirzepatide and Semaglutide
• Tirzepatide substance profile
• Semaglutide substance profile
• Retatrutide substance profile

Scientific References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022). PMID 35658024

2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine (2021). PMID 33567185

3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023). PMID 37366315

4. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021). PMID 34170647

5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine (2023). PMID 37952131